Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
07 sept. 2023 08h15 HE
|
Arcutis Biotherapeutics, Inc.
Results for adults and children ages 6 years and older from INTEGUMENT-OLE long-term extension trial highlight that 46.1% and 51.0% of patients who rolled over from the roflumilast cream treatment arm...
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
11 juil. 2023 09h58 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia...
Sublingual Allergy Immunotherapy Market Size to Surpass US$ 1.02 billion by 2033 at a CAGR of 9.1%| Persistence Market Research
12 juin 2023 09h45 HE
|
Persistence Market Research
New York, June 12, 2023 (GLOBE NEWSWIRE) -- The sublingual allergy immunotherapy (SLIT) market has been experiencing steady growth in recent years due to increasing prevalence of allergies and...
selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
30 mai 2023 04h00 HE
|
AKAMPION
Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity Dosing of MAD stage has been initiated; first results expected for late...
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
09 mai 2023 16h02 HE
|
Arcutis Biotherapeutics, Inc.
Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarterContinued expansion of commercial...
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
02 mai 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
A total of 652 children, ages 2 to 5, were enrolled in the studyTopline data expected in the third quarterAtopic dermatitis (AD) affects approximately 26 million adults and children in the United...
Invea Therapeutics Research to be Showcased at the Prestigious 2023 DDW Meeting
26 avr. 2023 08h10 HE
|
Invea Therapeutics
GUILFORD, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Invea Therapeutics (Invea), a biotechnology company developing an artificial intelligence (AI) and machine learning (ML) powered pipeline of...
Evelo Biosciences Provides Clinical Updates
26 avr. 2023 07h30 HE
|
Evelo Biosciences, Inc.
– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint –– Company will focus on development of extracellular vesicles (EVs) –– First EV...
Atopic Dermatitis Drugs Market Predicted to Garner USD 24.5 Bn by 2032, At CAGR 9.1% | Market.us Report
24 avr. 2023 20h57 HE
|
Market.Us
New York, April 24, 2023 (GLOBE NEWSWIRE) -- The atopic dermatitis drugs market size is projected to surpass around USD 24.5 billion by 2032 from USD 10.5 billion in 2022 and it is poised to reach a...
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting
18 mars 2023 07h00 HE
|
Arcutis Biotherapeutics, Inc.
New INTEGUMENT-1 and INTEGUMENT-2 data show a rapid and significant reduction in itch as early as 24 hours after the first application of roflumilast cream 0.15%Rapid and significant improvements were...